Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1456P - Impact of early palliative care in quality at the end of life in small cell lung cancer patients

Date

16 Sep 2021

Session

ePoster Display

Presenters

Nicolás Jiménez-García

Citation

Annals of Oncology (2021) 32 (suppl_5): S1076-S1083. 10.1016/annonc/annonc679

Authors

N. Jiménez-García1, L. Ronco-Dumas2, F. Rivas-Ruiz3, R. Quirós-López1, C. Flores-Guardabrazo4, C.M.M. Bravo3, Y. Jamal-Ismail Ortiz1, E. Pérez-Ruiz5, V. Navarro3, M.I. Carrasco-Zafra6, R. Gómez6, J.C. Domínguez2, D. Pérez3, I. Zarcos3, M. Robles3, A. Galeote3, P. Cantizani3, C. Quero3, A. Rueda Dominguez7, R. Villatoro3

Author affiliations

  • 1 Internal Medicine, Hospital Costa del Sol, 29603 - Marbella/ES
  • 2 Aecc Marbella, Asociación Española Contra el Cancer, 29603 - Marbella/ES
  • 3 Medical Oncology, Agencia Sanitaria Costa del Sol - Hospital Costa del Sol, 29603 - Marbella/ES
  • 4 Algeciras Norte, Área de Gestión Sanitaria Algeciras Norte, 11270 - Algeciras/ES
  • 5 Medical Oncology Ugc, Hospital Universitario Regional y Virgen de la Victoria.IBIMA, 29603 - Marbella/ES
  • 6 Cudeca Marbella, Fundacion Cudeca, 29603 - Marbella/ES
  • 7 Medical Oncology, UGC Oncol. Hosp Univer Regional y Virgen Victoria. IBIMA. Málaga, 29010 - Málaga/ES
More

Abstract 1456P

Background

Early palliative care (EPC) in patients with advanced cancer is associated with better quality of life and fewer cancer-related symptoms during the dying process and improved overall survival (OS). Patients with small cell lung cancer (SCLC) have a biologically aggressive disease, so early inclusion may be relevant to modify clinical practice guidelines.

Methods

We performed a retrospective cohort study of patients with SCLC diagnosed between 2009 and 2019. The primary outcome of the study was to correlate the EPC with quality indicators (QIs) at the end of life. EPC was considered if they were referred within 12 weeks after diagnosis. Quality indicators (QIs) for end-of-life cancer care that we used were defined as a six-point scale: home or hospice death, received opioids <7 days before death, not an intensive care unit admission, not a prolonged inpatient hospital admission (>14 days), not >1 emergency room visits, all in the last month of life, and no chemotherapy within 2 weeks before death. Overall survival (OS) was also assessed.

Results

Of 101 SCLC, 69.3% were male and 31.7% were female. The median age was 65 years (SD 9,013). A EPC was performed in 24.5% of the sample. There were no differences in clinical characteristics between both groups except for stage at diagnosis, extended disease, 92% in EPC vs 68.4% in non-EPC, p=0.038, and type of chemotherapy, carboplatin, 84% in EPC vs 57.9% in non-EI, p:0.034. The primary outcome EPC was associated with lower score in QIs at end of life (1.20 vs 1.87, p=0.018). These differences remained when adjusting for stage in the multivariate model. Patients with EPC used more morphine at the end of life (76% vs 50%, p=0.041) and had fewer visits to the emergency department (28% vs 55.3%, p:0.033). However, no differences were observed between prolonged admissions, chemotherapy received in the last 14 days before death and place of death. OS was 5.16 months (95% CI, 3.41-6.90) in EPC vs 9.01 months (95% CI, 7.25-10.77) in non-EPC, p=0.007.

Conclusions

EPC is related to less therapeutic aggressiveness at the end of life. Higher rate of extended disease could be related to worse prognosis and survival. SCLC should be referred to EPC to maximize the full benefits.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A. Rueda Dominguez: Financial Interests, Institutional, Advisory Board: Merck; Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Expert Testimony: Merck; Financial Interests, Institutional, Expert Testimony: Bristol Myers Squibb; Financial Interests, Institutional, Expert Testimony: Roche; Financial Interests, Institutional, Expert Testimony: Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.